AUBREY EYRE BOHNE: Open Payments
NPI 1073885810 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,210 in 173 payments from 36 companies in 2025. Trend: 2023 $19 · 2024 $2,196 · 2025 $3,210
Food & beverage: $3,168Education: $43
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 20 | $334 |
| Novo Nordisk Inc | 16 | $312 |
| Xeris Pharmaceuticals, Inc. | 15 | $246 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $181 |
| ABBVIE INC. | 12 | $179 |
| RECORDATI_RARE_DISEASES_INC. | 16 | $174 |
| Dexcom, Inc. | 8 | $170 |
| BETA BIONICS, INC. | 7 | $163 |
| Tandem Diabetes Care, Inc. | 6 | $139 |
| Almatica Pharma LLC | 6 | $138 |
Products named: Ozempic, Repatha, Kerendia, ISTURISA, Dexcom G6 Transmitter, iLet Bionic Pancreas, TERIPARATIDE, JARDIANCE.
Industry payments across NV — which companies pay providers there.
